Future of the Global NGS Oncology Market: Trends, Innovations, and Key Forecasts Through 2034

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

NGS Oncology Market Size Growth Forecast: What to Expect by 2025?
The scope of the next-generation sequencing oncology sector has experienced swift expansion lately, projected to increase its valuation from $17.36 billion this year to $19.33 billion next, reflecting an 11.3% compounded annual growth rate. This upward trajectory observed historically stems from several key factors: the increasing prevalence of cancer diagnoses, heightened investigation into the genetic underpinnings of tumors, greater societal understanding of the disease, the broadening of medical support systems, and the escalating requirement for individualized treatment methodologies.

How Will the NGS Oncology Market Size Evolve and Grow by 2029?
Projections indicate substantial expansion for the next generation sequencing (NGS) oncology sector, anticipating it will reach a valuation of $29.64 billion by 2029, reflecting an impressive compound annual growth rate (CAGR) of 11.3% over the anticipated period; this forthcoming uplift is fundamentally underpinned by several key factors, such as the burgeoning development of companion diagnostics, the escalating incidence rates of various cancers globally, augmented financial commitments from both governmental and private healthcare sectors, the broadening scope of clinical utility for these technologies, and the increasing adoption of precisely targeted therapeutic approaches, while concurrently, the market is being shaped by significant technological shifts, including the incorporation of artificial intelligence and machine learning methodologies, progress in isolating and analyzing individual cells, improvements in sequencing instrument capabilities, innovations within non-invasive liquid biopsy techniques, and the maturation of platforms designed for large-scale, rapid sequencing operations.

View the full report here:
https://www.thebusinessresearchcompany.com/report/ngs-oncology-global-market-report

What Drivers Are Propelling the Growth of NGS Oncology Market Forward?
The accelerating incidence of cancer is anticipated to be a major catalyst for the expansion of the Next-Generation Sequencing (NGS) oncology sector in the foreseeable future. Cancer, characterized by the unrestrained proliferation of aberrant cells capable of metastasizing throughout the body and thereby impairing standard physiological operations, presents a growing public health challenge. This escalation in reported cancer cases is predominantly attributed to the increasing longevity of the global population, given the direct correlation between advanced age and heightened cancer risk. NGS technology within oncology offers a critical solution to this burgeoning issue by facilitating the identification of cancer at earlier stages, ensuring accurate diagnosis, and tailoring treatment regimens based on in-depth genetic analysis of malignant tissues. For example, statistical data provided by the American Cancer Society in 2022 indicated approximately 20 million new cancer diagnoses worldwide, leading to 9.7 million fatalities; moreover, fueled mainly by demographic expansion, the worldwide cancer incidence is forecasted to reach 35 million diagnoses annually by the year 2050. Consequently, the continually rising tide of cancer cases secures the upward trajectory of the NGS oncology market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24337&type=smp

Which Emerging Trends Are Transforming the NGS Oncology Market in 2025?
Leading firms within the NGS oncology sector are channeling efforts into formulating groundbreaking methods, notably liquid biopsy research assays, which facilitate cancer identification and surveillance in a non-intrusive, contemporary manner by examining cell-free tumor DNA. This particular type of diagnostic examination scrutinizes bodily fluids, like blood, for the presence of cancer-linked genetic variations or distinct molecular indicators, thereby permitting cancer assessment and oversight without invasive procedures. Specifically, in August of 2024, the US biotechnology entity Illumina Inc., recognized for its expertise in next-generation sequencing technology, augmented its oncology offerings available to NovaSeq X Series clientele. This augmentation introduced the recently confirmed, high-capacity TruSight Oncology 500 (TSO 500 HT) alongside the refined TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) liquid biopsy research assay. These upgraded analytical tools empower testing centers to expand their oncology investigation scope across both tissue and liquid biopsy specimens, boasting superior sequencing performance, quicker execution cycles, and the unprecedented capacity on the NovaSeq X Series to handle substantially greater quantities of samples.

What Are the Key Segments in the NGS Oncology Market?
The ngs oncologymarket covered in this report is segmented -

1) By Sequencing Technology: Targeted Sequencing; Genomics; Transcriptomics; Epigenomics
2) By Offering: Platform; Kits; Services
3) By Workflow: Pre-Sequencing; Sequencing; Data Analysis
4) By Application: Genetic Screening; Hereditary Genetic Testing; Hematological Malignancies; Solid Tumors; Other Applications
5) By End User: Hospitals And Clinics; Clinical Research Organizations (CROs); Academic And Research Institutes; Pharmaceutical And Biotechnology Companies; Other End Users

Subsegments:
1) By Targeted Sequencing: Whole Exome Sequencing (WES); Amplicon-Based Sequencing; Hybridization-Based Sequencing
2) By Genomics: Whole Genome Sequencing (WGS); Structural Variant Detection; Copy Number Variation (CNV) Analysis
3) By Transcriptomics: RNA Sequencing; Single-Cell Transcriptomics; Non-coding RNA Analysis
4) By Epigenomics: DNA Methylation Sequencing; Chromatin Immunoprecipitation Sequencing; Histone Modification Analysis

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24337&type=smp

Who Are the Key Players Shaping the NGS Oncology Market's Competitive Landscape?
Major companies operating in the NGS oncology market are Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Eurofins Scientific SE, Illumina Inc., Qiagen N.V., Tecan Trading AG, Myriad Genetics, Takara Bio Inc., Beijing Genomics Institute (BGI), Caris Life Sciences, Foundation Medicine, Paradigm Diagnostics, Pacific Bioscience, Horizon Discovery Group plc , Creative-Biolabs, Xcelris Labs Ltd., Partek Inc., 4baseCare, SciGenom Labs Pvt. Ltd.

What Geographic Markets Are Powering Growth in the NGS Oncology Market?
North America was the largest region in the NGS oncology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the NGS oncology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24337

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.